Ontologies Classes Object Properties Data Properties Annotation Properties Individuals Datatypes Clouds

Class: Warnings_and_Precautions_ALECE

Annotations (1)

- rdfs:comment "Hepatotoxicity: Monitor liver laboratory tests every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. In case of severe ALT, AST, or bilirubin elevations, withhold, then reduce dose, or permanently discontinue ALECENSA. (2.3, 5.1) • Interstitial Lung Disease (ILD)/Pneumonitis: Immediately withhold ALECENSA in patients diagnosed with ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis have been identified. (2.3, 5.2) • Renal Impairment: Withhold ALECENSA for severe renal impairment, then resume ALECENSA at reduced dose upon recovery or permanently discontinue (2.3, 5.3). • Bradycardia: Monitor heart rate and blood pressure regularly. If symptomatic, withhold ALECENSA then reduce dose, or permanently discontinue. (2.3, 5.4) • Severe Myalgia and Creatine Phosphokinase (CPK) Elevation: Assess CPK every 2 weeks during the first month of treatment and in patients reporting unexplained muscle pain, tenderness, or weakness. In case of severe CPK elevations, withhold, then resume or reduce dose. (2.3, 5.5) • Embryo-Fetal Toxicity: ALECENSA can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.6, 8.1, 8.3)"(xsd:string)

Superclasses (1)

- '\'Alecensa_(Alectinib)_\''

Disjoints (8)

Adverse_Reactions_ALECE, Contraindications_ALECE, Dosage_and_Administration_ALECE, Dosage_Forms_and_Strengths_ALECE, Drug_Interactions_ALECE, Indications_and_Usage_ALECE, Use_in_Specific_Populations_ALECE, **Warnings_and_Precautions_ALECE**

OWL HTML inside